Brazil says no to Russia’s Sputnik V; approves AstraZeneca, Chinese vaccines for emergency use

The Brazil National Health Surveillance Agency (Anvisa)  declined the request to approve the Russian-developed Sputnik V vaccine against COVID-19 for emergency use in Brazil. While, emergency use of COVID-19 vaccines from China’s Sinovac Biotech Ltd and Britain’s AstraZeneca have been approved by the regulator. 

“The request was returned to Uniao Quimica, because it does not comply with the minimal criteria in particular, due to lack of permission for third phase of clinical trials, as well as in regards to issue dealing with the advanced production methods,” TASS quoted the Anivsa.

This comes after, Uniao Quimica, a partner of the Russian Direct Investment Fund (RDIF), contacted Anvisa, last year in the month of December, requesting permission to conduct the third stage of clinical trials for the Sputnik V vaccine in Brazil.

Anivsa stated that, considering previous experience of reviewing such applications, the decision could have been provided within 72 hours. However, later, the agency requested additional information on the vaccine.

Leave a Comment